We explored the comprehension of the informed consent in 77 cancer patients previously enrolled in randomised phase II or phase III clinical trials, between March and July 2011, at the San Raffaele Scientific Institute in Milano. We asked participants to complete an ad hoc questionnaire and analysed their answers. Sixty-two per cent of the patients understood the purpose and nature of the trial they were participating in; 44% understood the study procedures and 40% correctly listed at least one of the major risks or complications related to their participation in the trial. We identified three factors associated with comprehension of the informed consent: age, education and type of tumour/investigator team. We suggest several possible improvements of how to obtain informed consent that will increase patient awareness, as well as the validity and effectiveness of the clinical trials.
- Informed Consent
- Ethics Committees/Consultation
- Research Ethics
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Read the full text or download the PDF:
Other content recommended for you
- 620 Creating a culture of clinical research in the clinic: Integrating clinical trials into the care of patients with lupus
- Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis
- Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
- Clinical trial participation and aggressive care at the end of life in patients with ovarian cancer
- Engaging African ancestry participants in SLE clinical trials
- End-of-life care in a population-based cohort of cancer patients: clinical trial participation versus standard of care
- Off-trial access to experimental cancer agents for the terminally ill: balancing the needs of individuals and society
- Cross-sectional assessment of patient attitudes towards participation in clinical trials: does making results publicly available matter?
- Phase I oncology trials: why the therapeutic misconception will not go away
- Supporting positive experiences and sustained participation in clinical trials: looking beyond information provision